Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Q: The DeLorean DMC-12 (commonly referred to simply as the DeLorean as it was the only model ever produced by the company) is a sports car manufactured by John DeLorean's DeLorean Motor Company for the American market from 1981--83.

A: What year did DeLorean DMC-12 start?
****
Q: Hoping to rebound from a tough loss to the Patriots, the Bills would play their Week 2 home opener in an interconference duel with the Tampa Bay Buccaneers. This would be the first time that Buffalo ever hosted Tampa Bay in a regular season game, having played a preseason game with each other in 1977. In the first quarter, the Bills came out firing as quarterback Trent Edwards completed a 32-yard touchdown pass to wide receiver Lee Evans, safety Donte Whitner returning an interception 76 yards for a touchdown and kicker Rian Lindell making a 31-yard field goal. The Buccaneers would get on the board in the second quarter as quarterback Byron Leftwich completed a 42-yard touchdown pass to tight end Kellen Winslow, while Buffalo replied with Lindell getting a 43-yard field goal. Tampa Bay would close out the half as Leftwich completed an 8-yard touchdown pass to running back Carnell "Cadillac" Williams. After a scoreless third quarter, the Bills began to pull away as Lindell got a 43-yard field goal and Edwards completed a 43-yard touchdown pass to wide receiver Terrell Owens. The Buccaneers tried to rally as Leftwich completed a 6-yard touchdown pass to tight end Jerramy Stevens (with a failed two-point conversion), yet Buffalo closed out the game with Lindell nailing a 20-yard field goal. With the win, the Bills improved to 1-1.

A: Who won against the Bills before this game?
****
Q: Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P.05), and naproxen resulted in significant improvement of LBPI vs placebo (P.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.

A:
What is the target of tanezumab?
****